VolitionRx Limited (NYSEAMERICAN:VNRX), an epigenetics company, is joining the ranks of the Russell 3000 and Russell Microcap Indexes when they reconstitute at the close of trading on Friday, the company announced.
Roughly $9 trillion in assets are benchmarked against Russell Indexes in the US, the company said.
"Inclusion in the Russell Indexes is an important achievement for Volition,” CEO Cameron Reynolds said in a statement. “It is a testament to the significant progress we've made as a company over the past few years, and we believe that membership will provide further visibility within the financial community and greater liquidity in our shares."
READ: VolitionRx CEO to present coronavirus white blood cell research at Maxim Group virtual conference
Reynolds also released a business update video for investors.
"We look forward to introducing a wider investor audience to our platform and growth story, and to continuing to execute on our strategy in the second half of the year with several important milestones, including advancing our trials and an expected product launch, that further us on the path toward long-term value creation."
The company’s inclusion in the indexes will stand for at least the next year.
Volition is developing easy to use blood tests to help diagnose a variety of cancers and other diseases.
Contact Andrew Kessel at email@example.com
Follow him on Twitter @andrew_kessel